Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

(2010) P. L. Zinzani et al.   CLINICAL CANCER RESEARCH

The 51st Annual Meeting of the American Society of Hematology

(2010) Sonia Cunningham et al.   Clinical Lymphoma Myeloma & Leukemia

Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study

(2010) Julie E. Chang et al.   Clinical Lymphoma Myeloma & Leukemia

Front-line treatment of mantle cell lymphoma

(2010) C. H. Geisler   HAEMATOLOGICA

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

(2009) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia

(2009) Alessandra Ferrajoli   LEUKEMIA & LYMPHOMA

Interleukin-21: biology and application to cancer therapy

(2008) David J Andorsky et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study

(2008) Guillaume Cartron et al.   JOURNAL OF CLINICAL ONCOLOGY

GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas

(2008) Stephen J. Schuster et al.   LEUKEMIA & LYMPHOMA

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

(2008) Eva Kimby et al.   LEUKEMIA & LYMPHOMA